Abstract 58P
Background
There is an increasing incidence of RC in the young. Clinicopathologic features are not clearly established especially in the local Filipino population. Moreover, treatment challenges occur in this population. This study aims to describe the clinicopathologic profile and outcomes in patients diagnosed with RC in the young at the Southern Philippines Medical Center, Adult Cancer Institute.
Methods
All RC patients were reviewed from January 2018 to December 2021. A total of 548 RC patients were reviewed retrospectively.
Results
A total of 99 patients were identified (18%) as RC in the young. Majority were males (68%) and have a family history of cancer (72%). Mean tumor distance was 4.82+6.0 cm from the anal verge. All patients had adenocarcinoma histology with 9% having mucinous component and 1% with signet ring features. For tumor differentiation, 56% had moderately and 23% had poorly differentiated tumors. Most patients were diagnosed with locally advanced disease (55% St IIIB, 12% St IIIC) and 24% with distant metastasis. Mean CEA levels were elevated (preoperative 59.44ng/ml and post-operative 49.42ng/ml). Among non-metastatic disease, most stage II and stage III RC patients received neoadjuvant long course chemoradiation (LCCRT) then Surgery then adjuvant chemotherapy (AC) (52%). Most common AC used was Capecitabine-Oxaliplatin. At the time of analysis, 57.6% had no evidence of disease while 38.4% progressed or metastasized to distant organs. In the overall population of RC in the young, median overall survival was 21.3 months (mos). Survival rate at 12 mos was 60% and at 24 mos was 40%.
Conclusions
RC in the young Filipino patient presented more with lower lying rectal tumors, moderately to poorly differentiated histology, and more advanced disease at diagnosis. Survival appeared to be worse compared to historical data. Improved understanding of this specific subgroup is necessary for better treatment options and outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
Presenter: Gagandeep Kaur
Session: Poster viewing 02
110P - Neutrophil to lymphocyte ratio as a predictor of poor prognosis in advanced esophageal cancer
Presenter: Chaichana Chantharakhit
Session: Poster viewing 02
111P - Bicentric real-life analysis of the molecular portrait of patients with early onset metastatic biliary tract cancer
Presenter: Theresa Schmalfuss
Session: Poster viewing 02
112P - Prognostic role of sarcopenia before neoadjuvant chemoradiotherapy in patients with esophageal cancer: A retrospective study
Presenter: Mastaneh Sanei
Session: Poster viewing 02
113P - Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication
Presenter: Jun Liu
Session: Poster viewing 02
114P - Risk factors for oesophageal fistula: A life-threatening complication of treatment for oesophageal cancer
Presenter: Reo Omori
Session: Poster viewing 02
115P - Human epidermal growth factor receptor-2 (HER-2) expression status in patients with cholangiocarcinoma
Presenter: Thanit Imemkamon
Session: Poster viewing 02
116P - Spleen as an organ at risk (OAR) in adjuvant chemoradiotherapy of gastric cancer: Retrospective dosimetric single institutional experience
Presenter: Preethi Shetty
Session: Poster viewing 02
117P - Immunoprofile of adenosquamous carcinoma in gastric cancer
Presenter: Cheng-Han Wu
Session: Poster viewing 02
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02